NCT01674842View on ClinicalTrials.gov

Cisplatin + RT for Triple Negative Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

August 31, 2018

Study Completion Date

June 8, 2021

Conditions
Breast Cancer
Interventions
RADIATION

Radiation Therapy

Once daily, Monday - Friday for six weeks

DRUG

Cisplatin

Intravenously, once weekly for six weeks

Trial Locations (5)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

01757

Dana-Farber at Milford, Milford

02190

Dana Farber at South Shore Hospital, Weymouth

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT01674842 - Cisplatin + RT for Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter